GlassScriptPhysician profile
Jay Vakil
NPI 1881271278
$1,302.01
in general payments reported to CMS, 2019-2025
18 companies · $800 in 2025
The $800 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $502 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,203 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,203.01 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Springworks Therapeutics, INC. | $266.31 | 2024-2025 | Ogsiveo |
| Jazz Pharmaceuticals INC. | $149.38 | 2024 | |
| Incyte Corporation | $124.94 | 2025 | Jakafi |
| Adaptive Biotechnologies Corporation | $116.10 | 2024-2025 | Clonoseq |
| Lilly USA, LLC | $103.71 | 2024-2025 | Verzenio, Jaypirca |
| Pfizer INC. | $87.10 | 2025 | |
| Emd Serono, INC. | $82.56 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.16 | 2024-2025 | |
| Sobi, INC | $47.55 | 2025 | |
| Deciphera Pharmaceuticals INC. | $41.99 | 2025 | Romvimza, Qinlock |
| Genentech USA, INC. | $34.83 | 2025 | Itovebi |
| Mirati Therapeutics, INC. | $29.16 | 2024 | Krazati |
| Glaxosmithkline, LLC. | $29.00 | 2025 | Zejula, Jemperli |
| Genzyme Corporation | $27.97 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $24.49 | 2025 | Imfinzi |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.52 | 2025 | Keytruda, Keytruda Qlex |
| Beone Medicines USA, INC. | $22.99 | 2025 | Brukinsa |
| Pharmaand Gmbh | $20.25 | 2025 | Rubraca |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Vakil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.